VA-DXC-TECHNOLOGY
16.9.2019 15:02:12 CEST | Business Wire | Press release
Technology startups and scale-ups can pitch their innovation stories to insurance industry leaders and potentially showcase their solutions globally through the DXC Technology (NYSE: DXC) second annual DXC Invitational Americas . Competition finalists will have the opportunity to present before hundreds of insurance professionals at the DXC Insurance Conference 2019 , Nov. 11-14 in Miami.
The DXC Invitational Americas is one in a series of global competitions that aims to yield joint solutions to key insurance business challenges by tapping into top talent in the startup community. Late-stage startup and scale-up enterprises worldwide that have existing, market-ready products or solutions relevant to the insurance industry are encouraged to apply by midnight Eastern time on Oct. 6 to compete in two categories:
- Category 1: The Digital Insurance Ecosystem: A product or solution that can be integrated into the DXC Assure Digital Platform.
- Category 2: Enriching the Insurance Experience: A standalone product or solution with the capability to on-sell as a DXC service.
Competition finalists and winners will be selected by a panel of DXC insurance industry clients, other industry experts, and DXC leadership. DXC will continue to explore collaborative opportunities with winners, including partnership possibilities and engagement with its global client base, which represents 85 percent of the Global Fortune 500 insurance companies.
Winners and finalists will be invited to attend the DXC Insurance Conference, where they will present their innovations to several hundred DXC clients, partners and employees. The winners, including a “People’s Choice” winner, will be formally announced at the conference.
“As a world leader in insurance technology and services, DXC proactively pursues new ways of collaborating with insurtech companies to accelerate the innovation cycle and jointly leverage capabilities that will give DXC insurance clients ready access to the newest, most advanced technologies,” said Phil Ratcliff, vice president and general manager of Global Insurance, DXC. “The winning solutions from the 2019 DXC Invitational competition will become part of the DXC Assure Digital Platform, which makes innovative technology easily accessible to our insurance clients.”
In addition to the inaugural global DXC Invitational in 2018, the company has conducted regional invitationals in Australia, North and Central Europe, and India.
“We have enjoyed great success with previous Invitational winners, Mapcite [Australia 2018] and Surfly [Americas 2018],” said Faisal Siddiqi, chief technologist for innovation and ecosystems, DXC. “Our collaboration with insurtech companies further expands the value of our digital platform to bring even more creative solutions and innovations to insurers through such technologies as blockchain, artificial intelligence and internet of things for more compelling customer experiences.”
To participate in the DXC Invitational Americas 2019, apply here .
About DXC Technology
DXC Technology, the world’s leading independent, end-to-end IT services company, manages and modernizes mission-critical systems, integrating them with new digital solutions to produce better business outcomes. The company’s global reach and talent, innovation platforms, technology independence and extensive partner network enable more than 6,000 private- and public-sector clients in 70 countries to thrive on change. For more information, visit www.dxc.technology .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190916005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom